We hypothesized that ACTL6A promotes tumor progression in CRC by suppressing KLF4-mediated transcriptional activation of tumor-suppressive gene programs, particularly those linked to the P53 pathway. This evidence concerns the gene TP53 and colorectal carcinoma.